Search Result
| Isoforms Recommended: |
LTB4
|
Results for "
LTB 4
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
3
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-107608
-
-
-
- HY-149083
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
LTB4 antagonist 2, a carboxamide-acid compound, is an antagonist of leukotriene B4 (LTB4) with potentially anti-inflammatory activity. LTB4 antagonist 2 shows good affinity for the LTB4 receptor with IC50 of 439 nM .
|
-
-
- HY-149084
-
-
-
- HY-149082
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
LTB4 antagonist 1, a carboxamide-acid compound, is a potent Leukotriene B4 (LTB4) antagonist with an IC50 of 288 nM. LTB4 antagonist 1 has significant anti-inflammatory properties .
|
-
-
- HY-124100
-
-
-
- HY-131651
-
|
LTB4 ethanolamide
|
Endogenous Metabolite
Leukotriene Receptor
|
Cancer
|
|
Leukotriene B4 ethanolamide (LTB4 ethanolamide) is an antagonist and a partial agonist for Leukotriene B4 (LTB4) receptor 1 (BLTR1). Leukotriene B4 ethanolamide ameliorates the tumor progression, which is only asscociated with inflammation .
|
-
-
- HY-155204
-
|
|
Leukotriene Receptor
FLAP
|
Inflammation/Immunology
|
|
LTB4-IN-2 (Comopund 6x) is a Leukotriene B4 (LTB4) inhibitor. LTB4-IN-2 inhibits Leukotriene B4 formation (IC50: 1.15 μM) by selectively targeting 5-Lipoxygenase-activating protein (FLAP). LTB4-IN-2 can be used for anti-inflammatory research .
|
-
-
- HY-U00299
-
-
-
- HY-W747565
-
-
-
- HY-RS07873
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
LTB4R Human Pre-designed siRNA Set A contains three designed siRNAs for LTB4R gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
LTB4R Human Pre-designed siRNA Set A
LTB4R Human Pre-designed siRNA Set A
-
- HY-RS07874
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Ltb4r Rat Pre-designed siRNA Set A contains three designed siRNAs for Ltb4r gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Ltb4r Rat Pre-designed siRNA Set A
Ltb4r Rat Pre-designed siRNA Set A
-
- HY-RS07875
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Ltb4r1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ltb4r1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Ltb4r1 Mouse Pre-designed siRNA Set A
Ltb4r1 Mouse Pre-designed siRNA Set A
-
- HY-RS07876
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
LTB4R2 Human Pre-designed siRNA Set A contains three designed siRNAs for LTB4R2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
LTB4R2 Human Pre-designed siRNA Set A
LTB4R2 Human Pre-designed siRNA Set A
-
- HY-107608S
-
|
LTB4-d4; 5(S),12(R)-DiHETE-d4
|
PROTAC Linkers
Endogenous Metabolite
Leukotriene Receptor
|
Inflammation/Immunology
Cancer
|
|
Leukotriene B4-d4 is the deuterium labeled Leukotriene B4. Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2][3].
|
-
-
- HY-113879
-
|
18-Carboxy dinor LTB4
|
Others
|
Metabolic Disease
|
|
18-Carboxy dinor Leukotriene B4 (18-carboxy dinor LTB4) is a β-oxidation metabolite of LTB4. In the liver, LTB4 is rapidly metabolized to 20-carboxy LTB4, which then undergoes β-oxidation to 18-carboxy dinor LTB4.
|
-
-
- HY-113483
-
|
20-COOH LTB4
|
Drug Metabolite
Leukotriene Receptor
|
Metabolic Disease
|
|
20-Carboxy-Leukotriene B4 (20-COOH LTB4) is a metabolite of Leukotriene B4 (LTB4; HY-107608). 20-Carboxy-Leukotriene B4 binds to the BLT1 receptor with high affinity. 20-Carboxy-Leukotriene B4 inhibits LTB4-mediated neutrophil responses (migration, degranulation, leukotriene biosynthesis) .
|
-
-
- HY-137350
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
12-epi-LTB4 is an agonist for BLT1 and BLT2. 12-epi LTB4 exhibits a partial agonistic activity against mBLT1 and mBLT2, and induces phosphorylation of extracellular signal-regulated kinase in primary mouse keratinocytes .
|
-
-
- HY-107608A
-
|
5(S),12(S)-LTB4; 5(S),12(S)-DiHETE
|
Others
|
Others
|
|
5(S),12(S)-Leukotriene B4 (5(S),12(S)-LTB4; 5(S),12(S)-DiHETE) is a stereochemical isomer of LTB4 (HY-107608) .
|
-
-
- HY-130497
-
|
12-Oxo-LTB4
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
12-Oxo-leukotriene B4 (12-Oxo-LTB4) is an intermediate in the lipoxygenase-catalyzed path of Arachidonic acid (HY-109590) metabolism. 12-Oxo-leukotriene B4 is crucial in Leukotriene B4 metabolism and is involved in inflammation reactions . 12-Oxo-leukotriene B4 stimulates calcium levels in human neutrophils with an EC50 of 33 nM. 12-Oxo-leukotriene B4 induces migration of neutrophils with EC50 of 170 nM .
|
-
-
- HY-117896
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
SC-50605 and SC-51146 are second-generation leukotriene B4 (LTB4) receptor antagonists that effectively inhibit LTB4-induced chemotaxis in guinea pigs. SC-50605 targets the LTB4 receptor and has the potential to inhibit inflammatory diseases such as asthma, rheumatoid arthritis, and skin diseases. .
|
-
-
- HY-139112
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
Leukotriene B4 dimethyl amide, an immunomodulator, stimulates contraction of isolated guinea pig lung entities. Leukotriene B4 (LTB(4)) also stimulates human neutrophil migration, and LTB(4) antagonists may have anti-inflammatory activity in inflammatory pathophysiology .
|
-
-
- HY-123014
-
|
|
Others
|
Cancer
|
|
(Rac)-SC-45694 is a racemate of SC-45694. SC-45694 has full LTB4 agonist activity for neutrophil chemotaxis and has antagonist activity against LTB4-induced neutrophil degranulation .
|
-
-
- HY-112737
-
-
-
- HY-121621
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
RO5101576 is a potent LTB4 receptor antagonist with activity to inhibit LTB4-induced calcium mobilization and chemotaxis of human neutrophils. RO5101576 significantly attenuated LTB4-induced pulmonary eosinophilia in guinea pigs. RO5101576 inhibited allergen- and ozone-induced pulmonary neutrophilia in nonhuman primates with efficacy comparable to that of budesonide. RO5101576 had no effect on LPS-induced neutrophilia in guinea pigs and cigarette smoke-induced neutrophilia in mice and rats. RO5101576 performed well in toxicology studies and was well tolerated .
|
-
-
- HY-13628A
-
|
LY293111 sodium; VML 295 sodium
|
Leukotriene Receptor
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Etalocib (LY293111) sodium, an orally active leukotriene B4 receptor antagonist, inhibits the binding of [ 3H]LTB4, with a Ki of 25 nM. Etalocib sodium prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib sodium induces apoptosis .
|
-
-
- HY-114641A
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 hydrochloride interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with Ki values of 1.7 nM .
|
-
-
- HY-114641
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
BIIL-260 is a potent and long-acting orally active leukotriene B(4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with the Ki value of 1.7 nM .
|
-
-
- HY-15744
-
-
-
- HY-112741
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
SB-209247 is a selective, high affinity and orally active leukotriene B4 (LTB4) receptor antagonist with a Ki of 0.78 nM. SB-209247 blocks LTB4-induced Ca 2+ mobilization with an IC50 of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity .
|
-
-
- HY-13628
-
|
LY293111; VML 295
|
Leukotriene Receptor
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Etalocib (LY293111), an orally active leukotriene B4 receptor antagonist, inhibits the binding of [ 3H]LTB4, with a Ki of 25 nM. Etalocib (LY293111) prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib (LY293111) induces apoptosis .
|
-
-
- HY-100173
-
-
-
- HY-112742
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
CP-195543 is a potent, selective and orally active leukotriene B4 (LTB4) receptor antagonist with IC50s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration .
|
-
-
- HY-19304
-
|
BIIL 284
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
Amelubant (BIIL 284) is a potent, oral and long acting LTB4 receptor antagonist, negligibly binds to LTB4 receptor, with Kis of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a proagent of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity .
|
-
-
- HY-U00263
-
-
-
- HY-134123
-
|
LXB4 methyl ester
|
Others
|
Metabolic Disease
|
|
Lipoxin B4 (LXB4) methyl ester is a lipid soluble prodrug form of the transcellular metabolite LXB4. LXB4 is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 (LTB4; Item No. 20110) and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM.
|
-
-
- HY-105176
-
-
-
- HY-101408
-
|
cis-13,16,19-docosatrienoic acid; (13Z,16Z,19Z)-13,16,19-Docosatrienoic acid
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Docosatrienoic acid is a rare ω-3 fatty acid; inhibits LTB4 binding to pig neutrophil membranes with an Ki of 5 μM.
|
-
-
- HY-108396
-
-
-
- HY-117557
-
-
-
- HY-106929
-
|
CGS 25019C free base
|
Others
|
Cancer
|
|
Moxilubant (CGS-25019C;LTB-019) is an orally active BLT1 antagonist which inhibits LTB4 signaling with a potency of 2–4 nM. Moxilubant can be used for cancer research .
|
-
-
- HY-U00170
-
-
-
- HY-120539
-
-
-
- HY-117706
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
LY 292728 is a potent leukotriene B4 (LTB4) receptor antagonist. LY 292728 binds to human neutrophils with a Ki of 0.47 nM and binds to guinea pig lung membranes with a Ki of 0.04 nM .
|
-
-
- HY-106929B
-
|
CGS 25019C hydrochloride
|
Others
|
Cancer
|
|
Moxilubant hydrochloride (CGS-25019C hydrochloride) is an orally active BLT1 antagonist which inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant hydrochloride can be used for cancer research .
|
-
-
- HY-W073687
-
|
|
Apoptosis
|
Others
|
|
2,4,6-Triiodophenol is an orally active and potent leukotriene B4 (LTB4) synthesis inhibitor. 2,4,6-Triiodophenol can induce mouse blastocysts apoptosis .
|
-
-
- HY-10437A
-
|
MK-0633 tosylate
|
Lipoxygenase
|
Inflammation/Immunology
|
|
Setileuton tosylate is an inhibitor for 5-lipoxygenase, that inhibits the oxidation of arachidonic acid by recombinant human 5-LO, and the production of LTB4 in calcium ionophore-stimulated human whole blood, with IC50 of 3.9 and 52 nM, respectively .
|
-
-
- HY-15874
-
|
GSK2190915; AM-803
|
FLAP
Leukotriene Receptor
|
Inflammation/Immunology
|
|
Fiboflapon (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood .
|
-
-
- HY-15874A
-
|
GSK2190915 sodium salt; AM-803 sodium
|
FLAP
Leukotriene Receptor
|
Inflammation/Immunology
|
|
Fiboflapon sodium (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood .
|
-
-
- HY-101438
-
-
-
- HY-10437
-
|
MK-0633
|
Lipoxygenase
|
Inflammation/Immunology
|
|
Setileuton (MK-0633) is an inhibitor for 5-lipoxygenase, that inhibits the oxidation of arachidonic acid by recombinant human 5-LO, and the production of LTB4 in calcium ionophore-stimulated human whole blood, with IC50 of 3.9 and 52 nM, respectively .
|
-
- HY-N1942
-
|
5-Demethylnobiletin
|
Lipoxygenase
Leukotriene Receptor
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
5-O-Demethylnobiletin (5-Demethylnobiletin), a polymethoxyflavone isolated from Citrus jambhiri Lush., is a direct inhibition of 5-LOX (IC50=0.1 μM), without affecting the expression of COX-2. 5-O-Demethylnobiletin (5-Demethylnobiletin) has anti-inflammatory activity, inhibits leukotriene B (4)(LTB4) formation in rat neutrophils and elastase release in human neutrophils with an IC50 of 0.35 μM .
|
-
- HY-101438A
-
-
- HY-101579
-
|
|
COX
Lipoxygenase
Phospholipase
|
Inflammation/Immunology
|
|
LY 178002 is a potent inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2, with IC50 of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on cyclooxygenase.
|
-
- HY-123575
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
LY 245769, a omega-trifluoro analog, is a leukotriene E4 (LTE4) inhibitor. LY 245769 interfers the omega-oxidation of N-acetyl-LTE4 and leukotriene B4 (LTB4) with IC50s of 4 μM .
|
-
- HY-12995
-
|
|
FLAP
|
Cardiovascular Disease
Inflammation/Immunology
|
|
BI 665915 is an orally active and potent 5-lipoxygenase-activating protein (FLAP) inhibitor. BI 665915 inhibits FLAP production that blocks LTB4 biosynthesis in mice. BI 665915 is promising for research of various inflammatory diseases, including respiratory and cardiovascular diseases .
|
-
- HY-120606
-
|
|
Lipoxygenase
|
Inflammation/Immunology
|
A-78773 is a 5-lipoxygenase inhibitor. A-78773 can inhibit the formation of LTB4 in human whole blood and human neutrophils, with IC50 values of 85 nM and 20 nM, respectively. A-78773 can be used in the study of inflammation-related diseases .
|
-
- HY-117854
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
SB 201146 is an LTB4 receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma .
|
-
- HY-149589
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
11(Z),14(Z)-Eicosadienoic acid is a unsaturated fattly acid that inhibits [ 3H] leukotriene B4 (LTB4) binding to pig neutrophil membranes with a Ki of 3 μM. 11(Z),14(Z)-Eicosadienoic acid has inflammatory activities .
|
-
- HY-113628
-
|
VML-530
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
ABT-080 is an orally active inhibitor of leukotriene biosynthesis. ABT-080 simultaneously blocks the leukotriene pathways leading to the synthesis of LTB4 and LTC4, but does not inhibit PGH2 biosynthesis. ABT-080 can block bronchoconstriction and be used in the research of asthma and related inflammations
|
-
- HY-113484
-
|
LTB5
|
Others
|
Cancer
|
|
Leukotriene B5 (LTB5) is a leukotriene with diverse biological activities. It is a metabolite of eicosapentaenoic acid formed through the 5-lipoxygenase (5-LO) pathway. LTB5 increases contraction of bullfrog lung strips ex vivo in a concentration-dependent manner. In vivo, LTB5 (100 nM) reduces tumor volume in mice injected with Tm1 murine melanoma cells. LTB5 also elicits chemokinesis and lysosomal enzyme release from polymorphonuclear leukocytes (PMNLs) 20- to 30-fold less, and induces platelet aggregation 8-fold less, potently than LTB4.
|
-
- HY-138050
-
|
(-)-Nyasol; (Z)-Hinokiresinol; cis-Hinokiresinol
|
NO Synthase
Bacterial
Fungal
Parasite
Leukotriene Receptor
|
Infection
Inflammation/Immunology
|
|
Nyasol ((-)-Nyasol) is an active compound that has antifungal, antibacterial, antileishmanial, hyaluronidase inhibition activities. Nyasol inhibits LTB4 binding to human neutrophils. Nyasol suppresses neuroinflammatory response through the inhibition of I-κB degradation in LPS (HY-D1056)-stimulated BV-2 microglial cells .
|
-
- HY-113479
-
-
- HY-N1942R
-
|
|
Lipoxygenase
Leukotriene Receptor
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
5-O-Demethylnobiletin (Standard) is the analytical standard of 5-O-Demethylnobiletin. This product is intended for research and analytical applications. 5-O-Demethylnobiletin (5-Demethylnobiletin), a polymethoxyflavone isolated from Citrus jambhiri Lush., is a direct inhibition of 5-LOX (IC50=0.1 μM), without affecting the expression of COX-2. 5-O-Demethylnobiletin (5-Demethylnobiletin) has anti-inflammatory activity, inhibits leukotriene B (4)(LTB4) formation in rat neutrophils and elastase release in human neutrophils with an IC50 of 0.35 μM .
|
-
- HY-B0174A
-
|
|
Leukotriene Receptor
Antibiotic
|
Inflammation/Immunology
|
|
Olsalazine is a potent inhibitor of macrophages chemotaxis to LTB4 with an IC50 value of 0.39 mM, also reduces the synthesis of 5-hydroxyeicosatetraenoic acid (5-HETE), 11-HETE, 12-HETE, and 15-HETE in polymorphonuclear leukocyte (PMNL) and mononuclear cells (MNL). Olsalazine can be used for researching ulcerative colitis. Anti-inflammatory activity .
|
-
- HY-12995A
-
|
|
FLAP
|
Inflammation/Immunology
|
|
(S)-BI 665915 is an orally active oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 1.7 nM for FLAP binding. (S)-BI 665915 inhibits FLAP functional in human whole blood with an IC50 of 45 nM. (S)-BI 665915 demonstrates an excellent cross-species agent metabolism and pharmacokinetics (DMPK) profile and a dose-dependent inhibition of LTB4 production .
|
-
- HY-118848
-
|
|
Lipoxygenase
Leukotriene Receptor
|
Inflammation/Immunology
|
|
A63162 is a specific 5-lipoxygenase (5-LOX) inhibitor. A63162 inhibits mitogen (PHA)-induced horse mononuclear cell (BMC) proliferation and inhibits Calcimycin (HY-N6687)-induced leukotriene LTB4 synthesis at the same concentration. A63162 can be used in the study of chronic obstructive pulmonary disease, arthritis and inflammatory bowel disease .
|
-
- HY-14165A
-
|
(S)-BAY X 1005; (S)-DG-031
|
Leukotriene Receptor
FLAP
|
Inflammation/Immunology
|
|
(S)-Veliflapon ((S)-BAY X 1005) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC50 values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood .
|
-
- HY-115369
-
|
|
Biochemical Assay Reagents
|
Others
|
|
cis-13,16,19-Docosatrienoic acid methyl ester is an ester form of docosatrienoic acid, a rare omega-3 fatty acid not found in the normal phospholipid polyunsaturated fatty acid pool Easily detectable, it inhibits the binding of [3H]-LTB4 to porcine neutrophils at a concentration of 5 μM. Methyl docosatrienoate is more fat-soluble than the free acid and may be more desirable than the free acid in some formulations.
|
-
- HY-19443
-
|
|
Histamine Receptor
Lipoxygenase
|
Inflammation/Immunology
|
|
UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 inhibits LTB4 formation in human whole blood and reduces polymorphonuclear cell infiltration in mouse models. UCB-35440 inhibits histamine-stimulated bronchoconstriction and reduces skin inflammation in guinea pigs. UCB-35440 can be used for research on asthma and skin inflammation .
|
-
- HY-123008
-
|
|
Others
|
Others
|
|
Reproterol hydrochloride is a dual-acting beta2-adrenoceptor agonist and phosphodiesterase inhibitor. Reproterol hydrochloride is more potent than albuterol and feterol in stimulating cAMP production in human monocytes, demonstrating its potential in enhancing airway function. Furthermore, Reproterol significantly inhibited the production of LTB4, indicating its anti-inflammatory properties. Reproterol hydrochloride may have inhibitory effects in respiratory diseases such as asthma and COPD .
|
-
- HY-B0174AS1
-
|
|
Antibiotic
Leukotriene Receptor
Isotope-Labeled Compounds
|
Inflammation/Immunology
|
|
Olsalazine-d3 is deuterated labeled Olsalazine (HY-B0174A). Olsalazine is a potent inhibitor of macrophages chemotaxis to LTB4 with an IC50 value of 0.39 mM, also reduces the synthesis of 5-hydroxyeicosatetraenoic acid (5-HETE), 11-HETE, 12-HETE, and 15-HETE in polymorphonuclear leukocyte (PMNL) and mononuclear cells (MNL). Olsalazine can be used for researching ulcerative colitis. Anti-inflammatory activity .
|
-
- HY-14162
-
|
|
FLAP
|
Inflammation/Immunology
|
AM103 (free acid) is a selective FLAP inhibitor that can block the first step of the LT pathway, which is 5-LO activation. AM103 (free acid) can inhibit the production of LTB4 and cysteinyl leukotrienes (CysLT). AM103 (free acid) has anti-inflammatory activity in a mouse model of chronic lung inflammation and can extend the survival time of mice injected with platelet-activating factor. AM103 (free acid) can be used for research on respiratory diseases such as asthma .
|
-
- HY-103360
-
|
|
CCR
|
Inflammation/Immunology
|
|
J-113863 is a potent and selective CCR1 antagonist with IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively. J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect .
|
-
- HY-B0174AS2
-
|
|
Antibiotic
Leukotriene Receptor
Isotope-Labeled Compounds
|
Inflammation/Immunology
|
|
Olsalazine-d3, 15N is 15N and deuterated labeled Olsalazine (HY-B0174A). Olsalazine is a potent inhibitor of macrophages chemotaxis to LTB4 with an IC50 value of 0.39 mM, also reduces the synthesis of 5-hydroxyeicosatetraenoic acid (5-HETE), 11-HETE, 12-HETE, and 15-HETE in polymorphonuclear leukocyte (PMNL) and mononuclear cells (MNL). Olsalazine can be used for researching ulcerative colitis. Anti-inflammatory activity .
|
-
- HY-118156
-
|
|
Others
|
Others
|
|
L-699333 is a 5-lipoxygenase (5-LO) inhibitor belonging to the thieno[2,3,4-cd]indole class. This compound has a 2-ethoxybutyric acid side chain and is a potent inhibitor of the biosynthesis of 5-HPETE and LTB4 produced from human 5-LO, with ICm values of 22 nM, 7 nM, and 3.8 pM for human neutrophils and whole blood, respectively. L-699333 has shown anti-inflammatory and antiasthmatic effects in a variety of animal models, including rat pleurisy models, antigen-induced wheezing models, and awake macaque and sheep asthma models. Its inhibition of 5-LO is highly selective, with higher ICm values or stronger competitive inhibition in FLAP binding assays compared to inhibition of human 15-LO, porcine 12-LO, and ram epididymal cyclooxygenase. The racemic enantiomer 14g of L-699333 is the most potent enantiomer to date, with inhibitory effects similar to those of the known MK-0591, which has been shown in clinical trials to inhibit the biochemical effects of LTB4 biosynthesis in vitro and LTE4 excretion in urine.
|
-
- HY-155300
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
BLT2 antagonist-1 (compound 15b) is a selective BLT2 antagonist that inhibits the chemotaxis of CHO-BLT2 cells with an IC50 of 224 nM. BLT2 antagonist-1 does not inhibits the chemotaxis of CHO-BLT1 cells. BLT2 antagonist-1 also inhibits the binding of LTB4 and BLT2 with a Ki value of 132 nM. BLT2 antagonist-1 can be used for the research of the inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease .
|
-
- HY-112621
-
|
LTA4 methyl ester
|
Others
|
Inflammation/Immunology
|
|
Leukotriene A4 (LTA4) is synthesized in mast cells, eosinophils, and neutrophils from arachidonic acid by 5-lipoxygenase (5-LO), which exhibits both lipoxygenase and LTA4 synthase activities. LTA4 is rapidly metabolized by LTA4 hydrolase or LTC4 synthase to LTB4 or LTC4, respectively.2 LTA4, from leukocytes, is known to undergo transcellular metabolism in platelets, erythrocytes, and endothelial cells.3 Further metabolism of LTA4 by 15-LO leads to lipoxin biosynthesis.2 LTA4 as a free acid is highly unstable. The methyl ester is stable and can be readily hydrolyzed to the free acid as needed.
|
-
- HY-141635
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
cis-11,14-Eicosadienoic acid methyl ester is a more lipid soluble form of the ω-6 C20-2 fatty acid 11(Z),14(Z)-eicosadienoic acid, a naturally occurring PUFA. 11(Z),14(Z)-Eicosadienoic acid competitively inhibits inosine 5’-monophosphate dehydrogenase (Ki=3.1 μM) and inhibits the binding of LTB4 to its receptor on neutrophils (Ki=3.0 μM). Also, serum levels of eicosadienoic acids negatively correlate with degree of sleep disturbance.3 Eicosadienoic acids are converted by desaturases, in vivo, to eicosatrienoic acids, which are potent vasodilators.
|
-
- HY-117811
-
|
L-680574
|
Others
|
Others
|
|
(R,R)-MK 287 is a tetrahydrofuran derivative that effectively inhibits the binding of [3H]C18-PAF to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes with K1 values of 6.1 ± 1.5, 3.2 ± 0.7, and 5.49 ± 2.3 nM, respectively. The inhibition is stereospecific and competitive. Its racemate, L-668,750, is less potent, and its enantiomer, L-680574, is only 1/20 as potent as MK 287. MK 287 inhibits the binding of [3H]C18-PAF to human PMN membranes, reducing the affinity of the radioligand without changing the number of receptor sites. The binding of other radioligands (e.g., LTB4, LTC4, C5a, FMLP) to their specific receptors is unchanged at 1-10 microM MK 287. [3H]MK 287 binds to human platelet and PMN membranes with KD values of 2.1 ± 0.6 and 2.9 ± 1.2 nM. When tested on isolated human cells, MK 287 potently and selectively inhibits PAF-induced platelet aggregation (ED50 = 56 ± 38 nM or ED50 = 1.5 ± 0.5 nM for gel-filtered platelets) and elastase release from PMNs (ED50 = 4.4 ± 2.6 nM). In vivo studies, MK 287 inhibited PAF-induced lethality in mice (ED50 = 0.8 mg/kg oral) and PAF-induced bronchospasm in guinea pigs (ED50 = 0.18 mg/kg intraduodenally and 0.19 mg/kg intravenously). The inhibition of PAF-induced bronchospasm was accompanied by a rightward shift in the concentration-response curve for PAF-induced platelet aggregation measured in vitro.
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-115369
-
|
|
Drug Delivery
|
|
cis-13,16,19-Docosatrienoic acid methyl ester is an ester form of docosatrienoic acid, a rare omega-3 fatty acid not found in the normal phospholipid polyunsaturated fatty acid pool Easily detectable, it inhibits the binding of [3H]-LTB4 to porcine neutrophils at a concentration of 5 μM. Methyl docosatrienoate is more fat-soluble than the free acid and may be more desirable than the free acid in some formulations.
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Compare |
Product Name |
Species |
Source |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Species |
|
| Source |
|
| Tag |
|
| Accession |
|
| Gene ID |
|
| Molecular Weight |
|
| Purity |
|
| Endotoxin Level |
|
| Biological Activity |
|
| Appearance |
|
| Formulation |
|
| Storage & Stability |
|
| Shipping |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-107608S
-
|
|
|
Leukotriene B4-d4 is the deuterium labeled Leukotriene B4. Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2][3].
|
-
-
- HY-B0174AS1
-
|
|
|
Olsalazine-d3 is deuterated labeled Olsalazine (HY-B0174A). Olsalazine is a potent inhibitor of macrophages chemotaxis to LTB4 with an IC50 value of 0.39 mM, also reduces the synthesis of 5-hydroxyeicosatetraenoic acid (5-HETE), 11-HETE, 12-HETE, and 15-HETE in polymorphonuclear leukocyte (PMNL) and mononuclear cells (MNL). Olsalazine can be used for researching ulcerative colitis. Anti-inflammatory activity .
|
-
-
- HY-B0174AS2
-
|
|
|
Olsalazine-d3, 15N is 15N and deuterated labeled Olsalazine (HY-B0174A). Olsalazine is a potent inhibitor of macrophages chemotaxis to LTB4 with an IC50 value of 0.39 mM, also reduces the synthesis of 5-hydroxyeicosatetraenoic acid (5-HETE), 11-HETE, 12-HETE, and 15-HETE in polymorphonuclear leukocyte (PMNL) and mononuclear cells (MNL). Olsalazine can be used for researching ulcerative colitis. Anti-inflammatory activity .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-RS07873
-
|
|
|
siRNAs
Pre-designed siRNA Sets
|
|
LTB4R Human Pre-designed siRNA Set A contains three designed siRNAs for LTB4R gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS07874
-
|
|
|
siRNAs
Pre-designed siRNA Sets
|
|
Ltb4r Rat Pre-designed siRNA Set A contains three designed siRNAs for Ltb4r gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS07875
-
|
|
|
siRNAs
Pre-designed siRNA Sets
|
|
Ltb4r1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ltb4r1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS07876
-
|
|
|
siRNAs
Pre-designed siRNA Sets
|
|
LTB4R2 Human Pre-designed siRNA Set A contains three designed siRNAs for LTB4R2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
